Italia markets closed
Dow Jones
39.308,00 -23,90 (-0,06%) Nasdaq
18.188,30 +159,54 (+0,88%) Nikkei 225
40.913,65 +332,89 (+0,82%) EUR/USD
1,0815 +0,0028 (+0,26%) Bitcoin EUR
53.762,84 -1.918,17 (-3,44%) CMC Crypto 200
1.215,01 -46,17 (-3,66%)
Bristol-Myers Squibb Company (BRM.DE)
XETRA - XETRA Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
Alla chiusura: 05:38PM CEST
| Chiusura precedente | 37,24 |
| Aperto | 37,40 |
| Denaro | 37,25 x 37000 |
| Domanda | 38,15 x 43000 |
| Min-Max giorno | 37,19 - 37,98 |
| Intervallo di 52 settimane | 36,90 - 59,00 |
| Volume | |
| Media Volume | 5.069 |
| Capitalizzazione | 75,94B |
| Beta (mensile su 5 anni) | 0,44 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,89 |
| Prossima data utili | 25 apr 2024 |
| Rendimento e dividendo (futuro) | 2,23 (6,00%) |
| Data ex dividendo | 05 lug 2024 |
| Stima target 1A | N/D |
GlobeNewswireArbutus Appoints Two New Executives
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Chri
© 2024 Yahoo. Tutti i diritti riservati.